CD38 and cancer: Moreover, despite viral control with therapy, patients with chronic viral infections such as HBV and HIV carry a higher risk of developing inflammation-associated end-stage diseases, including cancer; therefore, an immunomodulatory therapy targeting CD38 to control excessive inflammation mediated by vigorous immune activation may demonstrate considerable therapeutic potential.